EGFR‐targeted monoclonal antibodies, such as cetuximab, are used to treat KRAS‐wild type metastatic colorectal cancer, but eventually, resistance to this therapy emerges (Bhattacharya, 2023; Sforza et al., 2016). Here, KRAS is linked to metastatic colorectal cancer.